Psych CASC / OSCE · Consultation-liaison psychiatry
Explaining depression treatment and tamoxifen antidepressant choice — CASC communication station
MRCPsych/FRANZCP-style station: explain depression in cancer, collaborative care, safe antidepressant choice with tamoxifen, suicide risk without stigma, and delirium as a medical syndrome.
On this page
Study tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes after reading time. You are the psychiatry registrar in the oncology clinic. The patient has major depression and is on tamoxifen; her partner attends.[1][5]
Candidate instructions. Explain that depression in cancer is common and treatable, not a moral failure. Outline collaborative care and a tamoxifen-aware antidepressant plan (avoid strong CYP2D6 inhibitors such as paroxetine/fluoxetine). Address death wishes compassionately with a safety plan. Explain prior night confusion as likely delirium — medical and often temporary — not permanent "madness." Check understanding and agree next steps with oncology.[1][2][3][4]
References5ShowHide
- [1]Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ, 2010.PMID 20142325
- [2]Sharpe M, Walker J, Holm Hansen C, et al. Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial Lancet, 2014.PMID 25175478
- [3]Fang F, Fall K, Mittleman MA, et al. Suicide and cardiovascular death after a cancer diagnosis N Engl J Med, 2012.PMID 22475594
- [4]Agar MR, Lawlor PG, Quinn S, et al. Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial JAMA Intern Med, 2017.PMID 27918778
- [5]Pitman A, Suleman S, Hyde N, et al. Depression and anxiety in patients with cancer BMJ, 2018.PMID 29695476